Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 121

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 121
---
 many of which are beyond our control. These factors include: 

•the commencement or termination of our collaborations; 

•the timing of achievement of specified milestones in the development of our products and services; 

•introductions of new or expanded products or services or new pricing policies by us or by our competitors; 

•changes in the status of our regulatory clearances, authorizations, approvals or applications, or those jointly developed with our collaborators; 

•where required, the results of clinical trials of our future products and services, those jointly developed with our collaborators or those of our competitors; 

•the success of competitive products or technologies; 

•announcements by us or our competitors of significant acquisitions, collaborators or divestitures; 

•changes in governmental regulations and regulatory or legal developments in the U.S. and other countries; 

•developments or disputes concerning patent applications, issued patents or other proprietary rights; 

•the recruitment or departure of key personnel; 

•actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; 

•variations in our financial results or those of companies that are perceived to be similar to us; 

•changes in the structure of healthcare payment systems; 

•market conditions in the life sciences, clinical diagnostics or drug discovery industry; 

•general economic, industry and market conditions; 

•sales of our securities, including sales by our directors, officers or significant shareholders; 

•speculation about our business in the media or the investment community; and 

•other factors, including factors unrelated to our operating performance or the operating performance of our competitors. 

In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of listed companies. If the market for stock in our industry or the stock market in general experiences uneven investor confidence, the market price of our common stock could decline for reasons unrelated to our business, operating results or financial condition. The market price of our common stock might also decline in reaction to events that affect other companies within, or outside, our industry even if these events do not directly affect us. Any decline in the market price of our common stock may impair our ability to raise capital through the sale of equity securities. 

In the past, securities class action litigation has often been instituted against companies following periods of volatility in their stock price. This type of litigation, if instituted against us, could result in substantial costs to us and divert our management’s attention and resources, which could seriously